Lapisteride

Lapisteride (CS 891) is an orally active 5α-reductase inhibitor. Lapisteride can be used in cancer research[1].

5 alpha Reductase

Reference compound

Metabolic Enzyme/Protease

Cancer-programmed cell death

Cancer

https://www.medchemexpress.com/lapisteride.html

99.0

Ethanol : 100 mg/mL (ultrasonic)

C[C@@]12[C@](CC[C@@H]2C(NC(C)(C3=CC=C(C=C3)OC)C)=O)([H])[C@@]4([H])[C@@](CC1)([H])[C@@]5([C@@](NC(C=C5)=O)([H])CC4)C

464.64

[1]Yada S, et al. Solid phase transition of CS-891 enantiotropes during grinding. Int J Pharm. 2003 Apr 14;255(1-2):69-79.

Room Temperature

-20°C, 3 years; 4°C, 2 years (Powder)

http://file.medchemexpress.com/batch_PDF/HY-106174/Lapisteride-DataSheet-MedChemExpress.pdf

http://file.medchemexpress.com/batch_PDF/HY-106174/Lapisteride-SDS-MedChemExpress.pdf

No Development Reported

142139-60-4